Authors' objectives: Ductal carcinoma in situ (DCIS), commonly referred to as stage 0 breast cancer, is defined as neoplastic proliferation of epithelial cells that are confined to the mammary ductal-lobular system. Advancements in routine screening mammography have seen a substantial increase in the number of DCIS cases diagnosed each year, yet the prognosis for a woman diagnosed with DCIS is not well defined. Current recommended treatment guidelines for DCIS include lumpectomy plus radiation, total mastectomy, or lumpectomy without radiation. Postsurgical treatment guidelines include the use of endocrine therapy and counseling for risk reduction, and physical examination/mammography every 6 to 12 months for 5 years. This uncertainty in prognosis results in inadequate treatment with elevated risk for recurrence of DCIS or other invasive breast carcinoma for some patients, and unnecessary treatment with risk of serious side effects for others; therefore, prognostic tools that reliably differentiate patients at high risk of recurrence from those at lower risk would be beneficial. The focus of this report is to assess the evidence that supports the use of the Oncotype DX DCIS assay (Genomic Health Inc.).

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=48446

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: Winifred S. Hayes, Inc